Article thumbnail

Withdrawal Of Maintenance Therapy For Cytomegalovirus Retinitis In Aids Patients Exhibiting Immunological Response To Haart

By Waib L.F., Bonon S.H.A., Salles A.C., Benard G., De Oliveira A.C.P., Pannuti C.S., Pedro R.D.J. and Costa S.C.B.

Abstract

Background: Before the introduction of highly active antiretroviral therapy (HAART), CMV retinitis was a common complication in patients with advanced HIV disease and the therapy was well established; it consisted of an induction phase to control the infection with ganciclovir, followed by a lifelong maintenance phase to avoid or delay relapses. Methods: To determine the safety of CMV maintenance therapy withdrawal in patients with immune recovery after HAART, 35 patients with treated CMV retinitis, on maintenance therapy, with CD4+ cell count greater than 100 cells/mm3 for at least three months, but almost all patients presented these values for more than six months and viral load < 30000 copies/mL, were prospectively evaluated for the recurrence of CMV disease. Maintenance therapy was withdrawal at inclusion, and patients were monitored for at least 48 weeks by clinical and ophthalmologic evaluations, and by determination of CMV viremia markers (antigenemia-pp65), CD4+/CD8+ counts and plasma HIV RNA levels. Lymphoproliferative assays were performed on 26/35 patients. Results: From 35 patients included, only one had confirmed reactivation of CMV retinitis, at day 120 of follow-up. No patient returned positive antigenemia tests. No correlation between lymphoproliferative assays and CD4+ counts was observed. Conclusion: CMV retinitis maintenance therapy discontinuation is safe for those patients with quantitative immune recovery after HAART.494215219ACTG, Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. New Engl. J. Med, 326: 213-220, 1992BERENGUER, J., GONZALEZ, J., PULIDO, J., Discontinuation of secondary prophylaxis in patients with cytomegalovirus retinitis who have responded to highly active antiretroviral therapy (2002) Clin. infect. Dis, 34, pp. 394-397BONON, S.H., MENONI, S.M.F., ROSSI, C.L., Surveillance of cytomegalovirus infection in haematopoietic stem cell transplantation patients (2005) J. Infect, 50, pp. 130-137CASSOUX, N., BODAGHI, B., KATLAMA, C., LEHOANG, P., CMV retinitis in the era of HAART (1999) Ocul. Immunol. Inflamm, 7, pp. 231-235CURI, A.L., MURALHA, A., MURALHA, L., PAVESIO, C., Suspension of anticytomegalovirus maintenance therapy following immune recovery due to highly active antiretroviral therapy (2001) Brit. J. Ophthal, 85, pp. 471-473DEAYTON, J.WILSON, J.R.SABIN, P. et al. - Recovery of antibody responses to Cytomegalovirus (CMV) Glycoprotein B (gB) following Highly Active Antiretroviral Therapy (HAART). In: CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS, 6., Chicago, 1999. p. 153DEAYTON, J.R., WILSON, P., SABIN, C., Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy (2000) Aids, 14, pp. 1163-1670DEGREZIA, M.G., ROBINSON, M., Ophthalmic manifestations of HIV: An update (2001) J. Ass. Nurses AIDS Care, 12, pp. 22-32FRANCISCI, D., TOSTI, A., PREZIOSI, R., Role of antigenemia assay in the early diagnosis and prediction of human cytomegalovirus organ involvement in AIDS patients (1995) Europ. J. clin. Microbiol. infect. Dis, 14, pp. 498-503GALLANT, J.E., MOORE, R.D., RICHMAN, D.D., KERULY, J., CHAISSON, R.E., Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group (1992) J. infect. Dis, 166, pp. 1223-1227GERNA, G., PICCININI, G., GENINI, E., Declining levels of rescued lymphoproliferative response to human cytomegalovirus (HCMV) in AIDS patients with or without HCMV disease following long-term HAART (2001) J. acquir. immune Defic. Syndr, 28, pp. 320-331GOLDBERG, D.E., SMITHEN, L.M., ANGELILLI, A., FREEMAN, W.R., HIV-associated retinopathy in the HAART era (2005) Retina, 25, pp. 633-649HALWACHS, G., ZACH, G., POGGLITSCH, H., A rapid immunocytochemical assay for CMV detection in peripheral blood of organ-transplanted patients in clinical practice (1993) Transplantation, 56, pp. 338-342HENDERSON, H.W., MITCHELL, S.M., Treatment of immune recovery vitritis with local steroids (1999) Brit. J. Ophthal, 83, pp. 540-545HOOVER, D.R., PENG, Y., SAAH, A., Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression (1996) Arch. Ophthal, 114, pp. 821-827JABS, D.A., VAN NATTA, M.L., KEMPEN, M.L., Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy (2002) Amer. J. Ophthal, 133, pp. 48-61JACOBSON, M.A., Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome (1997) New Engl. J. Med, 337, pp. 105-114JACOBSON, M.A., ZEGANS, M.A., PAVAN, M., Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy (1997) Lancet, 349, pp. 1443-1445JOUAN, M.SAVES, M.TUBIANA, M. et al. - A prospective multicentre study to evaluate the discontinuation of maintenance therapy for CMV Retinitis in HIV-patients receiving HAART. In: CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS, 6., Chicago, 1999JOUAN, M., SAVES, M., TUBIANA, M., Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy (2001) Aids, 15, pp. 23-31KARAVELLAS, M.P., PLUMMER, M.P., MACDONALD, D.J., Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy (1999) J. infect. Dis, 179, pp. 697-700KEANE, N.M., PRICE, P., STONE, S.F., Assessment of immune function by lymphoproliferation underestimates lymphocyte functional capacity in HIV patients treated with highly active antiretroviral therapy (2000) AIDS Res. hum. Retroviruses, 16, pp. 1991-1996LI, T.S., TUBIANA, R., KATLAMA, C., Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease (1998) Lancet, 351, pp. 1682-1686MACDONALD, J.C., KARAVELLAS, M.P., TORRIANI, F.J., Highly active antiretroviral therapy-related immune recovery in AIDS patients with cytomegalovirus retinitis (2000) Ophthalmology, 107, pp. 877-881MACDONALD, J.C., TORRIANI, F.J., MORSE, L.S., Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy (1998) J. infect. Dis, 177, pp. 1182-1187MARGOLIS, T.P., Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis (2000) Surv. Ophthal, 44, p. 455MITCHELL, S.M., MEMBREY, W.L., YOULE, M.S., Cytomegalovirus retinitis after the initiation of highly active antiretroviral therapy: A 2-year prospective study (1999) Brit. J. Ophthal, 83, pp. 652-655PANNUTI, C.S., KALLAS, E.G., MUCCIOLI, C., Cytomegalovirus antigenemia in acquired immunodeficiency syndrome patients with untreated cytomegalovirus retinitis (1996) Amer. J. Ophthal, 122, pp. 847-852PICCININI, G., COMOLLI, G., GENINI, G., Comparative analysis of human cytomegalovirus-specific CD4(+) T-cell frequency and lymphoproliferative response in human immunodeficiency virus-positive patients (2001) Clin. diagn. Lab. Immunol, 8, pp. 1225-1230POSTELMANS, L., GERARD, M., SOMMEREIJNS, B., CASPERS-VELU, L., Discontinuation of maintenance therapy for CMV retinitis in AIDS patients on highly active antiretroviral therapy (1999) Ocul. Immunol. Inflamm, 7, pp. 199-203POWDERLY, W.G., LANDAY, A., LEDERMAN, M.M., Recovery of the immune system with antiretroviral therapy: The end of opportunism? (1998) J. Amer. med. Ass, 280, pp. 72-77RUHSWURM, I., RIES, I., KREPLER, E., Control of cytomegalovirus retinitis after combination antiretroviral therapy (1999) Acta Ophthal. Scand, 77, pp. 471-473SALMON-CERON, D., Cytomegalovirus infection: The point in 2001 (2001) HIV Med, 2, pp. 255-259SMITH, M.A., BRENNESSEL, D.J., Cytomegalovirus (1994) Infect. Dis. Clin. N. Amer, 8, pp. 427-438SODERBERG-NAUCLER, C., NELSON, J.Y., Human cytomegalovirus latency and reactivation - a delicate balance between the virus and its host's immune system (1999) Intervirology, 42, pp. 314-321SORIANO, V., DONA, C., RODRIGUEZ-ROSADO, R., BARREIRO, P., GONZALEZ-LAHOZ, J., Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy (2000) Aids, 14, pp. 383-386STEININGER, C., PUCHHAMMER-STOCKL, E., POPOW-KRAUPP, T., Cytomegalovirus disease in the era of highly active antiretroviral therapy (HAART) (2006) J. clin. Virol, 37, pp. 1-9TAY-KEARNEY, M.L., JABS, D.A., Ophthalmic complications of HIV infection (1996) Med. Clin. N. Amer, 80, pp. 1471-1492TUFAIL, A., MOE, A.A., MILLER, M.J., Quantitative cytomegalovirus DNA level in the blood and its relationship to cytomegalovirus retinitis in patients with acquired immune deficiency syndrome (1999) Ophthalmology, 106, pp. 133-141TURAL, C.ROMEU, C.SIRERA, J. et al. - A 24 month follow-up of cytomegalovirus retinitis without secondary prophylaxis following highly active antiretroviral therapy. In: CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS, 6., Chicago, 1999. p. 153 (Abstract no. 455)TURAL, C., ROMEU, J., SIRERA, J., Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients (1998) J. infect. Dis, 177, pp. 1080-1083VAN DER BIJ, W., VAN SON, W.J., VAN DER BERG, A.P., Cytomegalovirus (CMV) antigenemia: Rapid diagnosis and relationship with CMV-associated clinical syndromes in renal allograft recipients (1989) Transplant. Proc, 21, pp. 2061-2064VRABEC, T.R., BALDASSANO, V.F., WHITCUP, S.M., Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts (1998) Ophthalmology, 105, pp. 1259-1264WEINBERG, A.WOHL, D.A.BARRETT, R.J. & VAN DER HORST, C. -Inconsistent reconstitution of cytomegalovirus-specific cell-mediated immunity in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. J. infect. Dis., 184: 707-712, 2001WHITCUP, S.M., FORTIN, E., LINDBLAD, A.S., Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis (1999) J. Amer. med. Ass, 282, pp. 1633-1637WOHL, D.A., KENDALL, M.A., OWENS, S., The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy (2005) HIV clin. Trials, 6, pp. 136-14

Year: 2015
OAI identifier: oai:repositorio.unicamp.br:REPOSIP/104338
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.repositorio.unicamp... (external link)
  • http://repositorio.unicamp.br/... (external link)
  • http://www.scopus.com/inward/r... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.